Akebia Therapeutics
Clinical trials sponsored by Akebia Therapeutics, explained in plain language.
Akebia Therapeutics
AKBA
NASDAQ
Biopharmaceutical company focused on kidney disease treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug AKB-9090 takes first steps in human safety trial Results expected Dec 2026 (estimated)
- New hope for FSGS: experimental drug enters Mid-Stage trial Results expected Jun 2027 (estimated)